Phase 2 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have been diagnosed with stable heart failure with preserved ejection fraction (HFpEF) — a type of heart failure where the heart still pumps a normal amount of blood but does not relax properly — and who are experiencing symptoms from this condition
Who may not be able to join:
- People who have been diagnosed with certain heart muscle conditions, such as hypertrophic cardiomyopathy (a thickening of the heart muscle) or conditions where abnormal substances build up in the heart (such as cardiac amyloidosis)
- People who have any other serious or active health condition that could affect study results or put them at risk during the trial
- There are additional criteria not listed here that the trial site will assess (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of treatment emergent adverse events (TEAEs); Incidence of serious adverse events (SAEs); Incidence of AEs leading to treatment discontinuation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.